The new oral antidiabetics have expanded our possibilities of treating type 2 diabetes and associated diseases. AGIs and insulin sensitizers represent new principles of action. The insulinotropic substances improve the dynamics of insulin secretion. They enable pathophysiologically-oriented treatment that takes account of the patient's need for simple, low-stress management. This improves the quality of life, in particular of the elderly and disabled patient. However, this fact does not justify delaying treatment with insulin, which is always needed when the goals of treatment cannot be achieved with oral preparations.